Alekseev, Boris
3 papers on CoChatORCID 0000-0002-3398-4128
Most cited papers
- Verified
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine
Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers
Cited by 3,403
- Verified
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 930
- Verified
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Motzer, R. J., Robbins, P. B., Powles, T., Albiges, L., Haanen, J. B., Larkin, J., Mu, X. J., Ching, K. A., Uemura, M., Pal, S. K., et al. (2020) · Nature Medicine
Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers
Cited by 518
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free